Health officials say a potential new weapon in the fight against melanoma is showing promising results. Moderna and Merck say ...

El éxito de una vacuna personalizada de ARNm contra la recurrencia del melanoma abre un gran espacio para esta tecnología y ...

Merck and Moderna’s success with a personalized cancer vaccine designed to keep melanoma at bay opens a ​new avenue of ...

The rally was primarily driven by the strong late-stage trial of Moderna Inc.’s (NASDAQ:MRNA) intismeran autogene—an ...

The announcement by Moderna Inc. and Merck & Co. that a messenger RNA-based cancer vaccine had lowered the recurrence rate ...

Scientists said the drug trial of the treatment for melanoma could be the beginning of a transformation in care.

The messenger RNA (mRNA) technology that became humanity's frontline defense during the COVID-19 pandemic has now crossed a ...

Tempus AI, Inc. made a timely move to acquire the Personalis cancer monitoring tests to advance AI-driven precision medicine.

The study also met a secondary goal of preventing cancer from spreading to different parts of the body.

Успех испытаний персонализированных мРНК-вакцин против меланомы от компаний Merck и Moderna открывает новую эру в лечении ...

Thử nghiệm giai đoạn 3 ghi nhận vaccine mRNA của Moderna và Merck giúp giảm mạnh nguy cơ tái phát ung thư hắc tố, mở đường ...

Merck y Moderna anunciaron los resultados de una terapia personalizada contra el melanoma. Le explicamos qué significan estos ...